Top 10 drugs from new Pfizer

The Associated Press has put out a helpful list of Merck's top-selling drugs for the fourth quarter, now that it has merged with Schering-Plough. So we thought we'd take a look at the other megamerger--Pfizer and Wyeth--and Merck's list, too. The names on both lists are familiar, and you'll notice that each list includes some drugs brought in by the respective mergers. Here's Pfizer's list to start:

Ver

* Lipitor, cholesterol drug, $3.175 billion, a 1 percent increase over the same period last year;

* Lyrica, for fibromyalgia and nerve pain, $820 million, a 17 percent increase;

* Celebrex, an arthritis pain drug, $669 million, up 1 percent;

* Viagra, erectile dysfunction, $549 million, up 9 percent;

* Xalatan/Xalacom, eye pressure, $499 million, up 10 percent;

* Norvasc, for high blood pressure, $486 million, down 10 percent;

* Zyvox, antibiotic, $330 million, up 16 percent;

* Detrol/Detrol LA, overactive bladder, $309 million, down 1 percent;

* Sutent, cancer treatment, $293 million, up 33 percent; and

* Geodon/Zeldox, antipsychotics, $289 million, up 5 percent.